DIRS.INFO The most relevant business & tech news

☆ Terminally ill Palestinian prisoner dies after 38 years in Israeli custody
▼ + stars: | 2024-04-09 | by ( Sahar Akbarzai | Kareem Khadder | ) edition.cnn.com time to read: +4 min

CNN —Walid Daqqa, one of the longest-serving Palestinian prisoners in Israel, died of cancer on Sunday at the age of 63 after almost four decades of incarceration. At the time of his death, he was the longest imprisoned Palestinian in Israel, with the second longest sentence served overall, according to the Palestinian Prisoners Society. Born in the Israeli town of Baqa al-Gharbiyye in the northern “triangle” region, Daqqa was a Palestinian citizen of Israel. Daqqa was not convicted of carrying out the murder but of commanding the group, which he denied, Amnesty said. After his death, a tent set up for mourners to gather on Monday in Baqa al-Gharbiyye was stormed by Israeli police, according to a statement from the Palestinian Prisoners Society and CNN video.

Persons: CNN — Walid Daqqa, Daqqa, Liberation of, Moshe Tamam, Tamam’s, Ortal, Israel, Daqqa “, ”, Addameer, Gharbiyye, Erika Guevara, Rosas, Ortal Tamam, “ Organizations: CNN, Palestinian Prisoners Society, Oslo Accords, Israel Prison Service, Popular Front, Liberation, Liberation of Palestine, Amnesty, Palestinian, West Bank, ” CNN, myelofibrosis, Research Locations: Israel, Oslo, Baqa, Palestinian

☆ Thom Felicia, member of 'Queer Eye' cast, believes that donating bone marrow to his brother was the best thing he has ever done
▼ + stars: | 2023-12-03 | by ( Kelly Burch | ) www.businessinsider.com time to read: +4 min

Ten years ago, he donated bone marrow to save his brother, who had blood cancer. AdvertisementMy brother was diagnosed with a rare blood cancerMy brother, Jules, is about five years older than me. I think everyone should consider bone marrow donationThe donation process was no problem for me. I've found there's a big difference between what people think bone marrow donation is, and what it really is. I am still a registered donor, and I would donate bone marrow to anyone.

Persons: Thom Filicia, —, I'm, Jules, He's, I'd, they'd, I've, Jules hasn't Organizations: Service, Straight, GSK Locations: New York City

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

☆ This European biotech company could rally nearly 45%, says Morgan Stanley
▼ + stars: | 2023-10-13 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Recent data for cancer treatment manufacturer MorphoSys AG suggests the German biotech's shares could see a significant rally, according to Morgan Stanley. "Despite increasing competition, our updated analysis suggests peak global sales of $1.6bn for pelabresib," analyst James Quigley wrote in a Friday note. "In addition, while some clinical risk remains, the data so far suggests that MANIFEST-2 has a good chance of success, which should drive significant upside in the shares," Quigley said. Shares have sold off nearly 25% since mid-September, compared to the Nasdaq Biotechnology Index down 4% over the same period. MOR XBI YTD mountain MorphoSys vs SPDR S & P Biotech ETF in 2023.

Persons: Morgan Stanley, James Quigley, Quigley, SPDR, — CNBC's Michael Bloom Organizations: MorphoSys, pelabresib, Nasdaq, MF, P Biotech

☆ GSK says FDA extends review period for experimental drug momelotinib
▼ + stars: | 2023-06-16 | by ( ) www.reuters.com time to read: 1 min

June 16 (Reuters) - British drugmaker GSK Plc (GSK.L) on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a type of bone marrow cancer called myelofibrosis. Momelotinib is not currently approved in any market. Reporting by Eva Mathews in Bengaluru; Editing by Dhanya Ann ThoppilOur Standards: The Thomson Reuters Trust Principles.

Persons: Momelotinib, Eva Mathews, Dhanya Ann Thoppil Organizations: drugmaker GSK, U.S . Food, Drug Administration, Thomson Locations: U.S, Bengaluru

☆ Mike Pride, Who Proved a Regional Newspaper Could Work, Dies at 76
▼ + stars: | 2023-05-12 | by ( Sam Roberts | ) www.nytimes.com time to read: +1 min

The cause was myelofibrosis, a rare type of blood cancer, his son Dr. Yuri Pride said. As The Monitor’s managing editor from 1978 to 1983 and its editor until he retired in 2008, Mr. Pride won the National Press Foundation’s Editor of the Year Award in 1987 for overseeing The Monitor’s eloquent coverage of the death of a hometown heroine, the astronaut and teacher Christa McAuliffe, in the explosion of the space shuttle Challenger. In 2008, Preston Gannaway of The Monitor won the Pulitzer Prize for feature photography for her intimate chronicle of a family coping with a parent’s terminal illness. Under Mr. Pride’s leadership, the New England Newspaper & Press Association named The Monitor New England newspaper of the year 19 times.

☆ This little-known biotech stock developing treatments for blood disorders could jump 80%, BMO says
▼ + stars: | 2023-03-23 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors should take a closer look at Disc Medicine as it develops treatments for blood disorders, according to BMO Capital Markets. Analyst Evan David Seigerman initiated coverage of Disc Medicine with an outperform rating and a $40 price target, saying that the firm's development of bitopertin to treat erythropoietic porphyrias and other blood disorders appears promising. IRON YTD mountain Disc Medicine shares YTD Last year, Disc Medicine went public in a reverse merger with biotechnology company Gemini Therapeutics, trading under the ticker symbol "IRON." Disc Medicine shares are up 8% this year. The analyst's $40 price target means that Disc Medicine shares can jump 84% from Wednesday's closing price.

☆ Incyte to discontinue late-stage trial for bone marrow cancer drug combination
▼ + stars: | 2023-03-03 | by ( ) www.reuters.com time to read: +1 min

March 3 (Reuters) - Drugmaker Incyte Corp (INCY.O) said on Friday it was stopping its late-stage trial of an experimental cancer drug after an interim analysis indicated the drug was unlikely to meet the main goal of the study, dragging its shares 2% lower in after-market trade. The study was aimed at determining the safety and effectiveness of adding parsaclisib to the use of its drug Jakafi, which is approved for the treatment of some types of myelofibrosis - a form of bone marrow cancer. Discontinuation of the study was not due to safety, the company said. Data from mid-stage study in December had demonstrated that addition of parsaclisib to Jakafi resulted in some reduction in spleen volume and improvement in symptom burden in patients with myelofibrosis. Reporting by Arshreet Singh; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

☆ Geron's blood cancer drug succeeds in late-stage study, shares surge
▼ + stars: | 2023-01-04 | by ( Sriparna Roy | ) www.reuters.com time to read: +2 min

Jan 4 (Reuters) - Geron Corp (GERN.O) said on Wednesday its experimental blood cancer drug helped more patients achieve independence from blood transfusions when compared with a placebo in a late-stage trial, sending its shares up 50%. Geron's lead drug, imetelstat, was being studied in patients with a type of myelodysplastic syndromes (MDS), a difficult to treat family of blood cancers. Patients with the disease require frequent blood transfusions to manage their anemia. The drug also met its secondary goal, with 28% of the patients using the drug not needing transfusion for 24 weeks, compared with 3.3% of the patients on placebo. Geron is also testing the drug for myelofibrosis, a rare type of bone marrow cancer, and expects an interim analysis in 2024.

Search resuls for: "myelofibrosis"

9 mentions found